Drugs / Tegilol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06284746 Background | Oct 2023 → Apr 2025 | Her2-receptor negative breast cancer, gastric carcinoma | Lin Chen | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegilol | “The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin.” NCT06284746 ↗ |
| Known as | S-1 | “The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin.” NCT06284746 ↗ |